Nicholas C. Bank

Nicholas C. Bank

Auto-generated profile, based on publicly available information

Nicholas C. Bank

Department of Orthopaedics, The University of North Carolina School of Medicine, Chapel Hill, NC

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2024 in Journal of the American Academy of Orthopaedic Surgeons
Verified
Journal Article
Closed access
NBNicholas C. Bank
Nicholas C. Bank
PSParshva Sanghvi
Parshva Sanghvi
CHChristian J. Hecht
Christian J. Hecht
RMR. Justin Mistovich
R. Justin Mistovich
Introduction: Posttraumatic osteoarthritis of the knee (PTOAK) is a known sequela of bony and soft-tissue articular knee injuries, although its historically reported prevalence is highly variable with no recent population-based studies. Methods: The TriNetX/US Collaborative Network database was queried to identify adult patients diagnosed with a history of knee trauma using ICD-10-CM coding. Primary outcomes measured were yearly incidence proportion (IP), incidence rate (IR), and prevalence of knee osteoarthritis in the United States from 2000 to 2022. Chi square analyses were conducted to compare outcomes across categorical data. Regression modeling was performed to project PTOAK epidemiology to 2030. Statistical significance was held at P < 0.05 for all analyses. Results: Nine hundred forty-eight thousand eight hundred fifty-three patients meeting criteria were identified. As of 2022, the IP of PTOAK was 5.93%, IR was 2.26 × 10 −4 cases/person-day, and prevalence was 21.1%. By strata in 2022, posttraumatic knee OA is most prevalent among the 54 to 59-year-old age group (50.9%), 60 to 64-year-old age group (50.3%), 50 to 54-year-old age group (49.7%), female patients (24.2%), and White patients (23.1%). Regression analyses revealed that the IP, IR, and prevalence of PTOAK have increased exponentially from 2000 to 2022. By 2030, the model predicts that the IP will further increase to 10.7% (95% PI = 9.79% to 11.7%), IR will be 3.79 × 10 −4 cases/person-day (95% PI = 3.28 × 10 −4 to 4.29 × 10 −4 ), and prevalence of PTOAK in the United States will be 40.6% (95% PI = 39.1% to 42.0%). Discussion: These findings echo earlier, smaller scale studies but reveal an alarming rise in PTOAK prevalence, potentially doubling by 2030. The financial burden of knee OA treatment in the United States is already substantial, costing between $5.7 and $15 billion USD annually. This projected increase in prevalence could further increase healthcare expenditures by $1 to 3 billion by 2030. These results emphasize the need for additional research into factors contributing to PTOAK, evidence-based preventive public health interventions, and the development of multidisciplinary system-based care delivery optimization pathways.

8 May 2025 in The Journal of Foot and Ankle Surgery
Verified
Journal Article
Closed access
JMJoshua Morningstar
Joshua Morningstar
BLBradley J Lauck
Bradley J Lauck
NBNicholas Bank
Nicholas Bank
TLTrapper Lalli
Trapper Lalli

20 December 2025 in World Neurosurgery
Verified
Journal Article
Open access
NBNicholas C. Bank
Nicholas C. Bank
DWDaniel Whittingslow
Daniel Whittingslow
SDSam Duggan
Sam Duggan
JMJoshua L. Morningstar
Joshua L. Morningstar
DWDouglas S. Weinberg
Douglas S. Weinberg
Pseudarthrosis remains a significant complication of ACDF, contributing to patient morbidity and increased healthcare costs. Glucagon-like peptide-1 receptor agonists (GLP-1RA), widely prescribed for diabetes and obesity, have been shown to reduced odds of pseudoarthrosis after ACDF. However, it remains unclear whether these reductions meaningfully translate to reduced odds of subsequent cervical surgery. The TriNetX United States Collaborative Network was queried for patients who underwent single- or multi-level ACDF between 2013-2023. Patients with perioperative GLP-1RA use and propensity-score-matched controls without GLP-1RA use were compared for subsequent rates of pseudoarthrosis and cervical reoperation at 6-, 12-, and 24-month intervals. Odds ratios (ORs) with 95% confidence intervals (CI) were calculated to determine differences in outcomes between cohorts. Following matching, 1592 patients were included in each cohort. GLP-1RA users demonstrated significantly reduced pseudarthrosis rates at all time points: 6 months (8% vs. 12%; OR=0.702; 95%CI=0.555-0.888), 12 months (OR=0.730; 95%CI=0.582-0.915), and 24 months postoperatively (OR=0.788; 95% CI=0.634-0.979). Reoperation odds among ACDF/GLP-1RA patients were significantly reduced at 12 months (4% vs. 6%; OR=0.689; 95%CI=0.493-0.963) and 24 months postoperatively (5% vs. 7%; OR=0.692; 95%CI=0.512-0.934). There were no statistically significant differences in outcomes between GLP-1RA users undergoing single-level versus multi-level ACDF. GLP-1RA use was associated with significantly reduced odds of pseudarthrosis by more than 20% and reoperation by more than 30% at 24 months following ACDF, suggesting that GLP-1RAs may improve postoperative outcomes in high-risk populations, offering a potential avenue for reducing complications and costs associated with ACDF. Level III, Retrospective cohort study.

21 May 2025 in Journal of Hand Surgery Global Online
Verified
Journal Article
Open access
NBNicholas C. Bank
Nicholas C. Bank
SPStephen J. Perle
Stephen J. Perle
BLBradley J. Lauck
Bradley J. Lauck
ARAlecia J. Rajesh
Alecia J. Rajesh
AJAlexander D. Jeffs
Alexander D. Jeffs
RDReid W. Draeger
Reid W. Draeger
Glucagon-like peptide-1 receptor agonist (GLP-1RA) use continues to rise because of its efficacy in glycemic control and weight reduction. There are sparse data on the implications of GLP-1RA therapy on surgical outcomes. Given the higher prevalence of carpal tunnel syndrome in patients with diabetes mellitus, obesity, or both, this study evaluated the impact of perioperative GLP-1RA use on both short-term (90-day) and long-term (1-year) postoperative complications in patients undergoing carpal tunnel release (CTR). A retrospective cohort analysis was conducted with the TriNetX research database and identified all patients who underwent CTR at 95 health care organizations between 2004 and 2024. Two cohorts were stratified by perioperative GLP-1RA use and propensity score matched (1:1) to mitigate baseline differences in demographics, comorbidities, and procedural approach. Primary outcomes, including scarring, wound dehiscence, and infection, were evaluated over a 90-day postoperative period, whereas secondary outcomes, including subsequent CTR and median nerve (MN) injury, were assessed at the 1-year follow-up. Cohorts were compared using odds ratios (OR) with 95% confidence intervals (CI). The query identified 303,360 patients who underwent CTR, including 13,439 on perioperative GLP-1RA therapy. After matching, homogeneous cohorts each consisted of 10,773 patients. At 90 days after surgery, the GLP-1RA cohort had significantly lower odds of wound dehiscence (OR, 0.691; 95% CI, 0.488–0.978) compared with patients not on GLP-1RA therapy. No significant differences were observed in rates of infection (superficial, deep, or unspecified), abscess incision and drainage, or scarring. At 1 year, GLP-1RA patients had lower odds of subsequent CTR (OR, 0.897; 95% CI, 0.839–0.959) and MN injury (OR, 0.399; 95% CI, 0.192–0.832). Perioperative GLP-1RA use was associated with a small yet statistically significant reduction in the odds of wound dehiscence following CTR and did not increase the odds of any other 90-day postoperative complications. Additionally, GLP-1RA therapy demonstrated lower odds of subsequent CTR and MN injury at the 1-year follow-up. Prospective investigation is warranted to further clarify the impact of GLP-1RA therapy in patients undergoing CTR. Prognostic III.

31 October 2025 in JSES Reviews, Reports, and Techniques
Verified
Journal Article
Open access
WDWilliam R. Davis
William R. Davis
NBNicholas C. Bank
Nicholas C. Bank
BLBradley J Lauck
Bradley J Lauck
RCRobert A. Creighton
Robert A. Creighton
RMR. Justin Mistovich
R. Justin Mistovich
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for managing type 2 diabetes mellitus (T2DM) and obesity due to their proven metabolic benefits. However, their impact on musculoskeletal conditions, particularly in non-weight-bearing joints such as the shoulder joint, remains unclear. This study aimed to determine whether GLP-1RA use was associated with the development of shoulder pathologies (glenohumeral osteoarthritis, adhesive capsulitis, atraumatic rotator cuff tears, and shoulder fractures) over a 5-year period. A retrospective cohort study was performed using the TriNetX research database. Adult patients prescribed GLP-1RAs between 2017 and 2019 were identified and stratified into 3 cohorts based on obesity (body mass index ≥30) and T2DM status: (1) obese T2DM, (2) nonobese T2DM, and (3) nonobese non-T2DM. Within each group, GLP-1RA users were 1:1 propensity score matched to nonusers. Primary outcomes (glenohumeral osteoarthritis, adhesive capsulitis, atraumatic rotator cuff tears, and shoulder fractures) were evaluated over a 5-year period, and secondary outcomes (hemoglobin A1c and body mass index) were assessed over a 2-year period. Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to compare incidence between GLP-1RA users and nonusers. At 5-year follow-up, GLP-1RA use was associated with higher incidence rates of glenohumeral osteoarthritis, adhesive capsulitis, and atraumatic rotator cuff tears across all subgroups as compared to nonusers. The highest increased risk was observed for adhesive capsulitis, particularly in the obese nondiabetic subgroup (HR: 2.465; 95% CI [3.173-1.916]). Shoulder fracture incidence was lower among GLP-1RA users with both obesity and T2DM (HR: 0.903; 95% CI [0.827-0.987]) but did not differ significantly in patients with obesity without T2DM or in nonobese patients with diabetes. GLP-1RA therapy was associated with an increased incidence of certain shoulder pathologies, most notably adhesive capsulitis, suggesting GLP-1RAs may have adverse musculoskeletal effects in the shoulder joint. These findings highlight the need for future prospective studies to confirm these associations.

2 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
NBNicholas C. Bank
Nicholas C. Bank
VSVaidhvi Singh
Vaidhvi Singh
BGBrandon Grubb
Brandon Grubb
BMBlake McCourt
Blake McCourt
ABAaron Burberry
Aaron Burberry
ARAlexander Rodriguez-Palacios
Alexander Rodriguez-Palacios
The causes for variability of pro-inflammatory surface antigens that affect gut commensal/opportunistic dualism within the phylum Bacteroidota remain unclear (1, 2). Using the classical lipopolysaccharide/O-antigen ‘ rfb operon’ in Enterobacteriaceae as a surface antigen model (5-gene-cluster rfbABCDX ), and a recent rfbA- typing strategy for strain classification (3), we characterized the architecture/conservancy of the entire rfb operon in Bacteroidota . Analyzing complete genomes, we discovered that most Bacteroidota have the rfb operon fragmented into non-random gene-singlets and/or doublets/triplets, termed ‘minioperons’. To reflect global operon integrity, duplication, and fragmentation principles, we propose a five-category (infra/supernumerary) cataloguing system and a Global Operon Profiling System for bacteria. Mechanistically, genomic sequence analyses revealed that operon fragmentation is driven by intra-operon insertions of predominantly Bacteroides -DNA ( thetaiotaomicron/fragilis ) and likely natural selection in specific micro-niches. Bacteroides -insertions, also detected in other antigenic operons (fimbriae), but not in operons deemed essential (ribosomal), could explain why Bacteroidota have fewer KEGG-pathways despite large genomes (4). DNA insertions overrepresenting DNA-exchange-avid species, impact functional metagenomics by inflating gene-based pathway inference and overestimating ‘extra-species’ abundance. Using bacteria from inflammatory gut-wall cavernous micro-tracts (CavFT) in Crohn’s Disease (5), we illustrate that bacteria with supernumerary-fragmented operons cannot produce O-antigen, and that commensal/CavFT Bacteroidota stimulate macrophages with lower potency than Enterobacteriaceae , and do not induce peritonitis in mice. The impact of ‘foreign-DNA’ insertions on pro-inflammatory operons, metagenomics, and commensalism offers potential for novel diagnostics and therapeutics.